ReviewMarine drugs2022
A Comprehensive Update on the Bioactive Compounds from Seagrasses.
Review in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Spatial Patterns and Overlap of Sedimentary and Rhizosphere Microbiomes of the Seagrass Zostera capensis.Environmental microbiology reports · 2026Article
- Quercetin and Citreorosein fromCurrent pharmaceutical design · 2026Article
- Potential Use of Marine Plants as a Source of Bioactive Compounds.Molecules (Basel, Switzerland) · 2025Review
- Article
- Exploring Fungal Diversity in Seagrass Ecosystems for Pharmaceutical and Ecological Insights.Journal of fungi (Basel, Switzerland) · 2024Review
- Review
- A Phytochemical Analysis and the Pharmacological Implications of the SeagrassPharmaceuticals (Basel, Switzerland) · 2024Review
- The In Vitro Antioxidant and Anti-Inflammatory Activities of Selected Australian Seagrasses.Life (Basel, Switzerland) · 2024Article
- Revealing Novel Source of Breast Cancer Inhibitors from SeagrassMolecules (Basel, Switzerland) · 2024Article
- Emerging Research Topics in the Vibrionaceae and the Squid-Microorganisms · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine angiosperms produce a wide variety of secondary metabolites with unique structural features that have the potential to be developed as effective and potent drugs for various diseases. Recently, research trends in secondary metabolites have led to drug discovery with an emphasis on their pharmacological activity. Among marine angiosperms, seagrasses have been utilized for a variety of remedial purposes, such as treating fevers, mental disorders, wounds, skin diseases, muscle pain, and stomach problems. Hence, it is essential to study their bioactive metabolites, medical properties, and underlying mechanisms when considering their pharmacological activity. However, there is a scarcity of studies on the compilation of existing work on their pharmacological uses, pharmacological pathways, and bioactive compounds. This review aims to compile the pharmacological activities of numerous seagrass species, their secondary metabolites, pharmacological properties, and mechanism of action. In conclusion, this review highlights the potency of seagrasses as a promising source of natural therapeutical products for preventing or inhibiting human diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.